Market Overview

Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference


Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced that
management will present at the upcoming Canaccord Genuity 38th Annual
Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

The Company will provide a corporate update and present upcoming
catalysts on Wednesday, August 8, 2018 at 2:00 p.m. ET. Interested
parties can access a live webcast of the presentation via a link from
Zymeworks' website at,
which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the
discovery, development, and commercialization of next-generation
multifunctional biotherapeutics. Zymeworks' suite of complementary
therapeutic platforms and its fully-integrated drug development engine
provide the flexibility and compatibility to precisely engineer and
develop highly-differentiated product candidates. Zymeworks' lead
product candidate, ZW25, is a novel bispecific antibody currently being
evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also
advancing a deep pipeline of preclinical product candidates and
discovery-stage programs in immuno-oncology and other therapeutic areas.
In addition to Zymeworks' wholly-owned pipeline, its therapeutic
platforms have been further leveraged through multiple strategic
partnerships with global biopharmaceutical companies.

View Comments and Join the Discussion!